Harvard Bioscience Inc.

NASDAQ: HBIO · Real-Time Price · USD
0.48
-0.05 (-9.06%)
At close: Aug 11, 2025, 3:59 PM

Harvard Bioscience Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
94.14M 112.25M 113.33M 118.9M
Cost of Revenue
39.37M 46.18M 52.52M 51.25M
Gross Profit
54.77M 66.07M 60.82M 67.65M
Operating Income
-6.21M 1.89M -7.17M 1.4M
Interest Income
n/a n/a n/a n/a
Pretax Income
-11.66M -2.56M -9.18M -140K
Net Income
-12.4M -3.42M -9.52M -288K
Selling & General & Admin
43.7M 46.89M 49.53M 48.95M
Research & Development
10.41M 11.76M 12.33M 10.8M
Other Expenses
6.87M 5.53M 6.12M 5.84M
Operating Expenses
60.98M 64.18M 67.98M 65.59M
Interest Expense
3.21M 3.59M 2.55M 1.54M
Selling & Marketing Expenses
22.21M 24.11M 25.04M 24.64M
Cost & Expenses
93.48M 110.36M 120.5M 116.84M
Income Tax Expense
740K 859K 337K 148K
Shares Outstanding (Basic)
43.54M 42.42M 41.41M 40.34M
Shares Outstanding (Diluted)
43.54M 42.42M 41.41M 40.34M
EPS (Basic)
-0.28 -0.08 -0.23 -0.01
EPS (Diluted)
-0.28 -0.08 -0.23 -0.01
EBITDA
-1.47M 8.03M 944K 11.31M
EBIT
-8.46M 1.03M -6.63M 3.69M
Depreciation & Amortization
6.98M 7M 7.58M 7.62M